- Home
- CLLS vs SEER Comparison
CLLS vs SEER Comparison
Compare CLLS & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SEER
- Stock Information
- Founded
- CLLS 1999
- SEER 2017
- Country
- CLLS France
- SEER United States
- Employees
- CLLS N/A
- SEER N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SEER Medicinal Chemicals and Botanical Products
- Sector
- CLLS Health Care
- SEER Health Care
- Exchange
- CLLS Nasdaq
- SEER Nasdaq
- Market Cap
- CLLS 148.1M
- SEER 124.9M
- IPO Year
- CLLS 2007
- SEER 2020
- Fundamental
- Price
- CLLS $1.45
- SEER $1.97
- Analyst Decision
- CLLS Buy
- SEER Hold
- Analyst Count
- CLLS 3
- SEER 1
- Target Price
- CLLS $7.00
- SEER $3.00
- AVG Volume (30 Days)
- CLLS 120.5K
- SEER 271.4K
- Earning Date
- CLLS 05-27-2025
- SEER 05-07-2025
- Dividend Yield
- CLLS N/A
- SEER N/A
- EPS Growth
- CLLS N/A
- SEER N/A
- EPS
- CLLS N/A
- SEER N/A
- Revenue
- CLLS $49,217,000.00
- SEER $14,170,000.00
- Revenue This Year
- CLLS $1.26
- SEER $23.54
- Revenue Next Year
- CLLS N/A
- SEER $42.98
- P/E Ratio
- CLLS N/A
- SEER N/A
- Revenue Growth
- CLLS 435.38
- SEER N/A
- 52 Week Low
- CLLS $1.10
- SEER $1.56
- 52 Week High
- CLLS $3.38
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- CLLS 60.38
- SEER 52.65
- Support Level
- CLLS $1.40
- SEER $1.97
- Resistance Level
- CLLS $1.56
- SEER $2.15
- Average True Range (ATR)
- CLLS 0.09
- SEER 0.11
- MACD
- CLLS 0.03
- SEER 0.04
- Stochastic Oscillator
- CLLS 76.09
- SEER 66.04
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.